Rigel Pharmaceuticals Advances R289 for Myelodysplastic Syndrome in Phase 1b Clinical Study

Rigel Pharmaceuticals Advances R289 for Myelodysplastic Syndrome Treatment

Rigel Pharmaceuticals, Inc. is making significant strides in the development of its investigational drug R289, a dual inhibitor targeting interleukin receptor-associated kinases 1 and 4 (IRAK1/4). The company has recently initiated the dose expansion phase of its Phase 1b clinical study, aiming to treat patients with transfusion-dependent relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). As of October 8, 2025, the first patient has been enrolled in this pivotal phase, which seeks to further evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289. The trial design includes a randomized approach where participants will receive either 500 mg of R289 once or twice daily, allowing researchers to assess the optimal dosing strategy for subsequent studies.

This expansion phase follows the successful completion of the dose escalation segment in July 2025, which laid the groundwork for the current study. A total of up to 40 patients will be enrolled in this trial, with the objective of establishing the recommended Phase 2 dose (RP2D). The FDA has recognized the potential of R289 by granting it Orphan Drug and Fast Track designations, highlighting the urgency in developing treatments for myelodysplastic syndromes and previously-treated transfusion-dependent lower-risk MDS. The ongoing study, registered under the identifier NCT05308264, aims to fill a crucial gap in addressing the unmet medical needs of lower-risk MDS patients, who frequently endure chronic inflammatory conditions resulting in persistent cytopenias.

Rigel Pharmaceuticals is optimistic about the future of R289 as it progresses through the clinical development pipeline. The company plans to release updated study data later this year, which will provide insights into the drug's effectiveness and safety profile. Furthermore, after determining the RP2D, Rigel intends to evaluate an exploratory cohort of erythropoiesis-stimulating agent (ESA) R/R lower-risk MDS patients. This strategic step is essential for refining the therapeutic landscape for MDS and potentially offering improved treatment options for patients grappling with this challenging condition.

In addition to the advancements with R289, Rigel Pharmaceuticals' focus on hematologic disorders reinforces its commitment to addressing critical health challenges. The dual-action mechanism of R289 positions it as a promising candidate in the fight against myelodysplastic syndromes, a group of disorders that significantly impact the quality of life for affected individuals. As the company moves forward, it continues to align its research efforts with the pressing needs of patients, striving for innovative solutions in the biotechnology sector.